Microbot Medical appoints Dr. Juan Diaz-Cartelle as CMO effective Dec 1, 2023

Microbot Medical Inc.

Dr. Diaz-Cartelle was previously Senior Medical Director at Boston Scientific (14 yrs) and Executive Medical Director at Haemonetics.
Base salary $350,000, target bonus up to 30% of salary, and 25,000 stock options vesting over three years.
He will lead U.S. clinical trials for the LIBERTY Endovascular Robotic Surgical System and FDA regulatory process.
Succeeds Dr. Eyal Morag; company shifts focus from R&D in Israel to U.S.-based clinical and commercial activities.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Juan Diaz-Cartelle

Chief Medical Officer

MBOT · Microbot Medical Inc.

Effective: 2023-12-01
Filed: November 21, 2023, 6:59 PM ET

On November 21, 2023, Microbot Medical Inc. (the “Company”) announced the appointment of Dr. Juan Diaz-Cartelle, age 48, as the Company’s new Chief Medical Officer (“CMO”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Juan Diaz-Cartelle was appointed as Chief Medical Officer at Microbot Medical Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

On November 21, 2023, Microbot Medical Inc. (the “Company”) announced the appointment of Dr. Juan Diaz-Cartelle, age 48, as the Company’s new Chief Medical Officer (“CMO”).

View on SEC.gov

Microbot Medical Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-042204

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.